PMID- 29381388
OWN - NLM
STAT- MEDLINE
DCOM- 20190613
LR  - 20190613
IS  - 1557-8992 (Electronic)
IS  - 1044-5463 (Linking)
VI  - 28
IP  - 4
DP  - 2018 May
TI  - Long-Acting Injectable Atypical Antipsychotic Use in Adolescents: An 
      Observational Study.
PG  - 252-257
LID - 10.1089/cap.2017.0096 [doi]
AB  - OBJECTIVES: Although second generation long-acting injectable antipsychotics 
      (SG-LAIAs) have been approved and are widely used in adults, there is limited 
      evidence for the use of long-acting formulations in children and adolescents. 
      Thus, we systematically describe the off-label use of SG-LAIAs in clinical 
      practice in adolescent inpatients. METHODS: All individuals admitted to our 
      Children and Adolescent Inpatient Psychiatry Unit receiving treatment with 
      SG-LAIAs between January 2013 and June 2016 were reviewed. A retrospective 
      analysis of medical records was conducted. Clinical diagnoses were established 
      using DSM-5 criteria. RESULTS: Thirty individuals (53.3% female) out of a total 
      of 1,148 admitted patients (2.6%) were identified. The mean age was 16.3 
      (SD = 1.3; range: 12.5-17.9).The main diagnoses were psychosis (70%) and 
      disruptive behavior disorders (DBDs) (30%), although comorbidity was frequent 
      (96.6%), especially drug use (55.2%, mostly cannabis). SG-LAIAs used were 
      aripiprazole (40%), risperidone (36.7%), and paliperidone palmitate (23.3%), and 
      the main reasons were a history of low compliance (90%) and/or poor insight 
      (73.3%). A mean improvement of 31.7 (SD = 8.7) between admission and discharge 
      was registered in the Children's Global Assessment Scale (CGAS); no differences 
      were observed between different SG-LAIAs. Although they were generally well 
      tolerated, 23.3% of patients reported mild short-term side effects, which were 
      more frequent with risperidone than with aripiprazole (p = .014). CONCLUSIONS: 
      Our clinical experience suggests that SG-LAIAs may be a safe treatment option 
      during adolescence in inpatients with psychotic disorders, as well as with DBD. 
      No differences were found in CGAS improvement scores between the three SGA-LAIAs 
      used, although patients on risperidone reported more side effects than those on 
      aripiprazole. Further research is needed so as to evaluate safety and 
      effectiveness of SG-LAIAs in this population.
FAU - Fortea, Adriana
AU  - Fortea A
AD  - 1 Department of Psychiatry and Psychology, Institute of Neuroscience, Hospital 
      Clinic de Barcelona , Barcelona, Spain .
FAU - Ilzarbe, Daniel
AU  - Ilzarbe D
AD  - 2 Department of Child and Adolescent Psychiatry, Institute of Psychiatry, King's 
      College of London , London, United Kingdom .
FAU - Espinosa, Laura
AU  - Espinosa L
AD  - 1 Department of Psychiatry and Psychology, Institute of Neuroscience, Hospital 
      Clinic de Barcelona , Barcelona, Spain .
FAU - Solerdelcoll, Mireia
AU  - Solerdelcoll M
AD  - 1 Department of Psychiatry and Psychology, Institute of Neuroscience, Hospital 
      Clinic de Barcelona , Barcelona, Spain .
FAU - de Castro, Clara
AU  - de Castro C
AD  - 3 Centro de Salud Mental Infanto-Juvenil, Hospital Sant Joan de Deu , Cornella de 
      Llobregat, Barcelona, Spain .
FAU - Oriolo, Giovanni
AU  - Oriolo G
AD  - 1 Department of Psychiatry and Psychology, Institute of Neuroscience, Hospital 
      Clinic de Barcelona , Barcelona, Spain .
FAU - Sugranyes, Gisela
AU  - Sugranyes G
AD  - 4 Department of Child and Adolescent Psychiatry, Institute of Neuroscience, 
      Hospital Clinic de Barcelona , Barcelona, Spain .
AD  - 5 Institut d'Investigacions Biomediques Agusti Pi i Sunyer (CERCA-IDIBAPS) , 
      Barcelona, Spain .
AD  - 6 Centro de Investigacion Biomedica en Red de Salud Mental (CIBERSAM) , 
      Barcelona, Spain .
FAU - Baeza, Inmaculada
AU  - Baeza I
AD  - 4 Department of Child and Adolescent Psychiatry, Institute of Neuroscience, 
      Hospital Clinic de Barcelona , Barcelona, Spain .
AD  - 5 Institut d'Investigacions Biomediques Agusti Pi i Sunyer (CERCA-IDIBAPS) , 
      Barcelona, Spain .
AD  - 6 Centro de Investigacion Biomedica en Red de Salud Mental (CIBERSAM) , 
      Barcelona, Spain .
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Observational Study
DEP - 20180130
PL  - United States
TA  - J Child Adolesc Psychopharmacol
JT  - Journal of child and adolescent psychopharmacology
JID - 9105358
RN  - 0 (Antipsychotic Agents)
RN  - 0 (Delayed-Action Preparations)
RN  - 82VFR53I78 (Aripiprazole)
RN  - L6UH7ZF8HC (Risperidone)
RN  - R8P8USM8FR (Paliperidone Palmitate)
SB  - IM
MH  - Adolescent
MH  - Antipsychotic Agents/adverse effects/*therapeutic use
MH  - Aripiprazole/adverse effects/therapeutic use
MH  - Attention Deficit and Disruptive Behavior Disorders/*drug therapy
MH  - Child
MH  - Delayed-Action Preparations
MH  - Female
MH  - Hospitalization
MH  - Humans
MH  - Inpatients
MH  - Male
MH  - Off-Label Use
MH  - Paliperidone Palmitate/adverse effects/therapeutic use
MH  - Psychiatric Status Rating Scales
MH  - Psychotic Disorders/*drug therapy/physiopathology
MH  - Retrospective Studies
MH  - Risperidone/adverse effects/therapeutic use
MH  - Treatment Outcome
OTO - NOTNLM
OT  - adolescent psychiatry
OT  - long-acting injectable antipsychotics
OT  - psychotic disorders
OT  - treatment efficacy
EDAT- 2018/01/31 06:00
MHDA- 2019/06/14 06:00
CRDT- 2018/01/31 06:00
PHST- 2018/01/31 06:00 [pubmed]
PHST- 2019/06/14 06:00 [medline]
PHST- 2018/01/31 06:00 [entrez]
AID - 10.1089/cap.2017.0096 [doi]
PST - ppublish
SO  - J Child Adolesc Psychopharmacol. 2018 May;28(4):252-257. doi: 
      10.1089/cap.2017.0096. Epub 2018 Jan 30.